Clinical Trial Update: Evaluation of Fidaxomicin in the Treatment of Clostridium Difficile Infection (CDI)

View source ↗

Summary

A clinical trial evaluating fidaxomicin for Clostridioides difficile infection has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Drugs mentioned

• Dificid (fidaxomicin)

Snippet

Sponsor: University of Pittsburgh | Conditions: Clostridium Difficile Infection (CDI) | Status: WITHDRAWN